INCA - The role of chronic INfections in the development of CAncer (FP6-LIFESCIHEALTH) (2006-01-01 - 2009-12-31) (»add to infobox)

Thomas Friedrich SCHULZ, Charles Richard Mark BANGHAM, Maria Grazia MASUCCI, Thomas F. MEYER, Thomas IFTNER, Agnès LABIGNE, Francis MÉGRAUD, Jean Elizabeth CRABTREE, Jose Carlos MACHADO, Susanne KRÜGER KJAER, Massimo TOMMASINO, Barbara FITZKY, Werner ZWERSCHKE, Luc WILLEMS, Vincenzo CIMINALE, Ralph GRASSMANN, Lawrence YOUNG, George MOSIALOS, Päivi OJALA, Mario LUPPI, Olle NILSSON, Bruno CUCINELLI, Harald MISCHAK, Michael PAWLITA, György KÉRI, Jochen KÖNIG, Staffan NORMARK

MEDIZINISCHE HOCHSCHULE HANNOVER (DE929 - Region Hannover) (Germany), IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (UKI11 - Inner London - West) (Great Britain), KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden), MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV (DE212 - München, Kreisfreie Stadt) (Germany), EBERHARD-KARLS UNIVERSITAET TUEBINGEN (DE142 - Tübingen, Landkreis) (Germany), INSTITUT PASTEUR (FR101 - Paris) (France), UNIVERSITE VICTOR SEGALEN - BORDEAUX II (FR612 - Gironde) (France), UNIVERSITY OF LEEDS (UKE42 - Leeds) (Great Britain), INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO (PT114 - Grande Porto) (Portugal), KRAEFTENS BEKAEMPELSE - DANISH CANCER SOCIETY (DK001 - København og Frederiksberg kommuner) (Denmark), INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FR716 - Rhône) (France), AMYNON BIOTECH GMBH (AT332 - Innsbruck) (Austria), OESTERREICHISCHE AKADEMIE DER WISSENSCHAFTEN (AT130 - Wien) (Austria), FACULTE UNIVERSITAIRE DES SCIENCES AGRONOMIQUES DE GEMBLOUX (BE352 - Arr. Namur) (Belgium), UNIVERSITA DEGLI STUDI DI PADOVA (ITD36 - Padova) (Italy), FRIEDRICH-ALEXANDER UNIVERSITAET ERLANGEN-NUERNBERG (DE25 - Mittelfranken) (Germany), THE UNIVERSITY OF BIRMINGHAM (UKG31 - Birmingham) (Great Britain), ARISTOTELIO PANEPISTIMIO THESSALONIKIS (GR122 - Thessaloniki) (Greece), HELSINGIN YLIOPISTO (FI181 - Uusimaa) (Finland), UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA (ITD54 - Modena) (Italy), FUJIREBIO DIAGNOSTICS AB (SE0A2 - Västra Götalands län) (Sweden), ARTTIC SA (FR101 - Paris) (France), MOSAIQUES DIAGNOSTICS GMBH (DE929 - Region Hannover) (Germany), DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (DE125 - Heidelberg, Stadtkreis) (Germany), VICHEM CHEMIE RESEARCH LTD (HU101 - Budapest) (Hungary), GENEDATA AG (CH056 - Graubünden) (Switzerland), SMITTSKYDDSINSTITUTET (SE010 - Stockholms län) (Sweden)

Approximately 17% of human cancer cases occurring world-wide are caused by one of 6 human viruses, Human papillomavirus (HPV), Epstein Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human herpesvirus 8 (HHV8; Kaposi´s sarcoma herpesvirus) and Human T- cell leukemia virus I (HTLV-I). In addition, the bacterium Helicobacter pylori is the infectious agent responsible for the second highest number of infection-associated cancers and additional infectious etiologies of cancer are likely to exist. The INCA Integrated Project aims towards a better understanding of (1) the molecular and cellular circuits involved in the development of cancers caused by these infectious agents, (2) the mechanisms of long-term persistence of these infectious agents in apparently healthy hosts, and (3) which genetic factors contribute to cancer development. Based on this knowledge INCA will develop and validate (4) animal models to study chronic inflammation and cancer progression, and (5) new diagnostic procedures for the identification of infected individuals likely to develop infection-associated malignancies. This will ultimately lead to (6) the identification of new drugs and procedures to interfere with processes that are central to the development of infection-associated cancer. The results of this joint effort will contribute to our understanding of malignant transformation and provide us with new tools to address an urgent socio-economic and human need. The INCA consortium will take a multi-disciplinary approach to the realisation of these goals and brings together scientists including SMEs from different backgrounds, who will work at all levels of a prevention and therapy-oriented process. The organisation of the research themes and joint activities in INCA subprojects will ensure the rapid spread of new findings into the entire programme. Professional management will promote efficient integration, realisation of scientific objectives & knowledge dissemination.

PERSONS (27/27)

RELATED NAVIGATION AREA(S) (3/3)